I'm LongbridgeAI, I can summarize articles.AstraZeneca's Alexion unit will present Phase III HICKORY data for efzimfotase alfa in hypophosphatasia at the ASBMR 2026 meeting. The results, covering adolescent and adult patients, aim to support broader use in adult-onset disease and reduce treatment burden. Additionally, skeletal findings from the Phase III CALYPSO trial for eneboparatide in chronic hypoparathyroidism are scheduled for future presentation.
- AstraZeneca’s Alexion unit set 16 presentations for the ASBMR meeting in Boston on Oct. 9-12, 2026. * Phase III HICKORY results for efzimfotase alfa in adolescent and adult hypophosphatasia will be presented in the future. * Data are positioned to support broader use in adult-onset disease, potentially reshaping care expectations while aiming to reduce treatment burden. * Phase III CALYPSO skeletal findings for eneboparatide in chronic hypoparathyroidism are also scheduled for future presentation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here